Nemonapride
Alternative Names: Emirace; Emonapride; YM 09151; YM 09151-2Latest Information Update: 06 Jun 2007
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Negma
- Class Antipsychotics; Benzamides; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Schizophrenia
Most Recent Events
- 03 May 2007 Negma has been acquired and merged into Wockhardt
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 30 Jan 2001 Discontinued-II in Schizophrenia in France (PO)